What Desloratadine Labormed Treats: Main Uses and Benefits

Desloratadine Labormed is generally applied across domains where the body's heightened physiological activity to allergens causes systemic discomfort, primarily focusing on symptomatic relief to ease the overall symptom burden. The medication is relevant for easing symptoms related to key allergic conditions. The medicine is used for managing conditions that are characterized by periods of heightened symptoms, including Allergic Rhinitis (both seasonal and perennial) and Chronic Idiopathic Urticaria (hives).

It is used for managing symptom clusters that create noticeable physiological strain, which may include frequent sneezing, persistent runny nose, ocular itching, and severe pruritus. The medication provides support that helps ease the overall symptom burden, generally assisting patients in coping more steadily when these symptoms interfere with routine activities.

QuickFact: Relief for Systemic Discomfort
Symptom focus: Nasal, ocular, and dermal manifestations.
Context: Conditions involving episodic, chronic, or fluctuating symptom patterns.
Benefit: Helps maintain a sense of stability and contributes to improved day-to-day comfort.

Eligibility Scope

Scope	Detail
Populations for whom use is allowed:	Adults and adolescents 12 years of age and older. Children 6 months of age and older are approved for use in specific oral formulations for conditions like perennial allergic rhinitis.
Populations for whom use is contraindicated:	Individuals with known hypersensitivity to desloratadine, loratadine, or any of the formulation's excipients. This includes patients with specific hereditary excipient intolerances for tablet forms.
Age-related eligibility rules:	The safety and efficacy of the medicine are not established for infants under six months of age. Film-coated tablets are typically restricted to ages 12 years and older.
Condition-specific eligibility rules:	Patients with severe hepatic impairment or severe renal impairment should use the medicine with caution, and a formal dosage adjustment is recommended due to altered drug clearance.
Pregnancy and lactation eligibility status:	Pregnancy: Preferable to avoid use as a precautionary measure. Lactation: A decision to discontinue the drug or discontinue nursing is required, as the drug is known to pass into breast milk.
Eligibility-related restrictions:	Caution is officially recommended for patients with a medical or familial history of seizures.

---

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use the medicine by classifying individuals based on factors such as age thresholds and physiological status. Absolute exclusion is mandated by the contraindication against use in patients with drug component allergies. Use is limited for populations with impaired organ function or a history of seizures, while the label specifies that use is not established in the youngest pediatric groups due to insufficient data.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Desloratadine Labormed, based on authoritative government regulatory documents.

---

Documented Pharmacokinetic Interactions

The primary interaction involves a pharmacokinetic effect where co-administered medicines increase the systemic exposure of desloratadine. Co-administration with the following substances results in increased plasma concentrations (AUC/Cmax) of desloratadine and its active metabolite:

• Macrolide antibiotics (e.g., Erythromycin)
• Azole antifungals (e.g., Ketoconazole)
• H2-receptor antagonists (e.g., Cimetidine)
• Antidepressants (e.g., Fluoxetine)
• Azithromycin

Although these medicines increase exposure, regulatory clinical trials reported that this change was not associated with clinically important changes in the safety profile.

---

Substance and Food Constraints

Substance	Official Regulatory Statement
Food & Grapefruit Juice	No effect on the bioavailability of desloratadine is documented.
Alcohol	Clinical trials showed no potentiation of performance-impairing effects. However, post-marketing reports have documented cases of alcohol intolerance or intoxication.

---

Population-Specific Notes

The official labeling notes that patients with hepatic impairment (liver disease) or renal impairment (kidney disease) exhibit a documented increase in desloratadine exposure compared to healthy subjects. Furthermore, individuals identified as poor metabolizers show a significantly greater systemic exposure to the drug.

Antagonism of the Histamine H1 Receptor

Desloratadine functions primarily as an inverse agonist and antagonist that selectively targets the peripheral Histamine H1 Receptor ( H1-R). This mechanism blocks the receptor, preventing the inflammatory mediator histamine from binding and initiating its associated signaling cascade. This action on the H1-R results in the physiological modulation of vascular dynamics and peripheral sensory nerve stimulation.

---

Dual Modulation of Inflammation and Systemic Selectivity

Beyond simple receptor blockade, the drug supports a secondary anti-inflammatory modulation by non-competitively suppressing the release of various other pro-inflammatory mediators (cytokines and chemokines) from immune cells. The drug's molecular properties result in minimal activity within the central nervous system, concentrating its modulating effects on peripheral pathways. This combination of H1 antagonism and mediator suppression results in a physiological modulation of the systemic allergic response.

Desloratadine Labormed is designated strictly for oral administration across all its approved formulations, which include the film-coated tablet, the orally disintegrating tablet (ODT), and the oral solution. The official dosing schedule for this medication is standardized to a once-daily frequency for all approved age groups, maintaining a consistent rhythm of intake.

---

Standardized Dosing and Frequency

The standard dose for adults and adolescents 12 years of age and older is 5 mg once daily. The dosing for pediatric patients is tiered by age, starting at 1 mg once daily for infants aged 6 to 11 months, increasing to 1.25 mg for children 1 to 5 years, and 2.5 mg for children 6 to 11 years. These specific amounts ensure appropriate exposure across developmental stages.

Administration Context and Adjustments

The medication can be taken without regard to meals, allowing for flexibility in daily scheduling as food intake does not impact its proper use. Treatment duration is not fixed but is defined by the pattern of symptoms, permitting intermittent use (stopping when symptoms resolve) or continuous use for persistent conditions.

A procedural adjustment is required for adult patients diagnosed with kidney or liver impairment, where the recommended starting dose is 5 mg every other day. For the oral solution, a calibrated measuring device must be used for administration. If a dose is missed, it should be taken when remembered, but the patient should not double the dose to compensate.

Research evidence / Overview of studies for Desloratadine Labormed

Evidence Base for Allergic Rhinitis (AR)

Research has primarily explored how symptoms are measured in contexts related to conditions characterized by fluctuating or episodic manifestations, such as Allergic Rhinitis. The evidence base is largely built upon Short-term Randomized Controlled Trials (RCTs), where patients were observed over defined time intervals, typically two to four weeks. These studies involved comparisons against a placebo (an inactive substance) or, in some cases, against an active comparator.

These trials examined outcomes related to physical discomfort, specifically by measuring changes in Total Symptom Scores (TSS), which capture a composite of nasal and ocular symptoms. Research focused on episodes where symptoms become more noticeable, tracking individual patient-reported outcomes describing perceived discomfort such as sneezing, runny nose, itching of the eyes and nose, and tearing. Studies also recorded objective changes, including measurements of Nasal Airflow. Findings describe patterns observed in the studies over the short-term observation period, noting measured changes in symptoms in the observed populations relative to placebo. This research contributes to the broader evidence landscape.

Evidence Base for Urticaria (Hives)

The research supporting the use of Desloratadine Labormed for symptoms of Urticaria, or hives, was explored in Short-term Randomized Controlled Trials (RCTs). These studies primarily focused on patients with Chronic Idiopathic Urticaria (CIU), a standard model used to examine the Chronic Idiopathic Urticaria (CIU) condition model.

In these trials, research explored changes in outcomes related to systemic or functional imbalance, tracking the visible, physical discomfort associated with the condition. The key outcomes tracked were objective and subjective changes in dermal manifestations, including Pruritus (itching) scores and objective measurements of Wheal (hive) size and number. Studies report how symptoms evolved in the observed populations over the study periods.

Study Durations and Long-term Follow-up

Research has explored short-term symptom changes through pivotal studies typically conducted over intervals of two to four weeks. This means that follow-up durations were limited in many cases. Long-term outcomes are not well characterized by large-scale, controlled studies that track patients for several months or years. Evidence helps contextualize how patients reported their experience during the short trial period, but there is limited information that addresses whether the observed patterns are maintained over extended periods or if the effect can be sustained over extended periods of use.

Research in Specific Populations

Research was studied for its impact across various age groups. Study populations included Adults and Adolescents, and children have been evaluated for certain formulations. However, results apply only to the populations studied, meaning the applicability to other groups or conditions must be considered within the limitations of the existing research. Studies have also examined specific groups with comorbid conditions, such as patients diagnosed with both Allergic Rhinitis and concurrent mild asthma. Findings describe group patterns, not personal outcomes, for these specific subsets.

Key Studies & References DailyMed: Desloratadine Tablet Labeling and Indications for Use

Common questions about Desloratadine Labormed (FAQ)

Q: How quickly does Desloratadine Labormed usually start working in the body?

Clinical studies have examined the time-to-onset of the antihistaminic effect, indicating activity may be measurable by 1 hour after taking a single dose. Official product information notes this characteristic as observed in trials.

Q: Is Desloratadine Labormed intended to treat only seasonal allergies?

Official regulatory indications confirm that the medicine is approved for more than just seasonal conditions. The recognized uses include relief of symptoms associated with Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis (year-round), and Chronic Idiopathic Urticaria (chronic hives).

Q: Does Desloratadine Labormed help relieve nasal congestion?

Clinical study data for the single-ingredient formulation suggested efficacy in relieving most symptoms of allergic rhinitis, but generally excluded nasal congestion itself. For patients with congestion, official documents confirm the use of combination products that pair desloratadine with a decongestant like pseudoephedrine for comprehensive relief.

Q: Does Desloratadine Labormed cause weight gain or an increase in appetite?

Post-marketing surveillance, which collects reports after the drug is released, has included reports of increased appetite and weight increase. Official regulatory documents classify the frequency of these reports as 'Not known,' meaning it cannot be reliably estimated from available data.

Q: Can Desloratadine Labormed affect a person's ability to drive or operate machinery?

Official regulatory documents indicate that patients may be advised to avoid engaging in activities requiring mental alertness, such as driving or operating heavy machines. This recommendation reflects the need for patients to be aware of their individual response to the medicine before performing such tasks.

Q: Does Desloratadine Labormed increase skin sensitivity to sunlight (photosensitivity)?

Regulatory documents include photosensitivity reactions among the adverse effects reported during post-marketing surveillance. The frequency of these events is classified as 'Not known,' indicating it cannot be reliably estimated based on the clinical trial data.

Q: What are the signs of a rare, serious allergic reaction to Desloratadine Labormed?

Official documents document serious, rare hypersensitivity events, including Anaphylaxis and Angioedema. The reported physical signs associated with these events include severe rash, hives (urticaria), swelling (edema), and difficulty breathing (dyspnea).

Q: Is it safe to consume alcohol while taking Desloratadine Labormed?

While clinical trials did not show potentiation of alcohol's performance-impairing effects, official labeling notes that caution is warranted due to post-marketing reports of alcohol intolerance and intoxication. The product information describes this specific constraint.

Q: Does Desloratadine Labormed interact with common non-prescription cold or flu medications?

The active ingredient in this medicine is found in approved combination products that also contain a decongestant like pseudoephedrine for treating cold symptoms. However, official product information generally recommends avoiding co-administration of Desloratadine Labormed with other antihistamines or general cough and cold medicines.

Q: Is the use of Desloratadine Labormed studied in older adult (geriatric) patients?

Pharmacokinetic studies were conducted in older adults, specifically subjects 65 years of age and older. The results of these studies indicated that there was no meaningful difference observed in the drug's calculated parameters within this population compared to younger adults.

Q: Does Desloratadine Labormed contain ingredients that are important for people with Phenylketonuria (PKU) to know about?

The film-coated tablet formulation typically contains lactose as an inactive ingredient, or excipient. Regulatory safety warnings note that patients with rare hereditary issues like galactose intolerance or glucose-galactose malabsorption should not take this specific formulation.

Q: How does Desloratadine Labormed differ from its parent compound, Loratadine?

Desloratadine is classified as the active metabolite of the older antihistamine loratadine. This means the drug is already in its ready-to-act form in the body. It is a long-acting tricyclic histamine antagonist with specific H1-receptor activity.

Q: Is Desloratadine Labormed usually available over-the-counter (OTC) or only by prescription?

The legal classification of the medicine varies depending on the specific country or region. In some regulatory territories, it is classified as a Prescription-Only Medicine (POM), while in others, it may be available Over-The-Counter (OTC) without a prescription.

Q: Why do official sources suggest caution when stopping Desloratadine Labormed if a patient experiences seizures?

Regulatory documents state that healthcare providers may consider discontinuing desloratadine in patients who experience a new-onset seizure while receiving treatment. This specific warning is noted, especially concerning young children, who may be more susceptible to this type of event.

Storage and Disposal Requirements

Storage Conditions

Desloratadine should be stored at room temperature, typically between 20 C and 25 C (68 F and 77 F), and must not be stored above 30 C. The medication must be kept in the original package to ensure protection from light and moisture. Liquid formulations (oral solution/syrup) are required to be kept from freezing. For certain tablet containers, the product must be used within 3 months of first opening.

Safety and Disposal

It is officially mandated that Desloratadine must be stored out of the sight and reach of children, typically in a high, secure location with safety caps locked. Disposal of any unused or expired product must be done in accordance with local requirements. The medicine should not be disposed of via wastewater, and regulatory guidance recommends mixing unwanted tablets with an unappealing substance before discarding in the household trash if a drug take-back program is unavailable.